Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886795 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
A Phase 1 study of Urticaria, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00886795 is a Phase 1 study of Urticaria that has completed, run by Johns Hopkins University. The registered enrollment target is 4 participants, below the 59-participant average among 3 other Urticaria trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00886795, a Phase 1 study of Urticaria, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).
Conditions Studied
Interventions
- DRUG abatacept (Orencia ®)
Study Locations (1)
Maryland
- Johns Hopkins Arthritis Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00886795
The ClinicalTrials.gov registry entry for NCT00886795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 3 other Urticaria trials with a reported enrollment target (93% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urticaria appearing as the primary indexed condition, and to 1 intervention - of which abatacept (Orencia ®) is the first listed.
NCT00886795 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00886795 about?
NCT00886795 is a clinical study titled "Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy". This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).
What is the current status of trial NCT00886795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-05. Estimated completion is 2013-03.
What conditions does trial NCT00886795 study?
This clinical trial studies the following conditions: Urticaria.
What interventions are being tested in trial NCT00886795?
The interventions under investigation include: abatacept (Orencia ®) (DRUG).
Who is sponsoring clinical trial NCT00886795?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00886795 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.